Remdesivir-Associated Significant Bradycardia: A Report of Three Cases

Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond...

Full description

Saved in:
Bibliographic Details
Published inJournal of Tehran University Heart Center Vol. 16; no. 2; pp. 79 - 83
Main Authors Shirvani, Maria, Sayad, Babak, Shojaei, Lida, Amini, Azadeh, Shahbazi, Foroud
Format Journal Article
LanguageEnglish
Published Iran Tehran University of Medical Sciences 01.04.2021
Tehran University of Medical Sciences, 2006
Subjects
Arrhythmias; cardiac
Atropine
Bradycardia
Cardiac arrhythmia
Cardiovascular diseases
Case Report
Coronaviruses
COVID-19
Health risks
Heart rate
Pacemakers
Patients
Prolongation
Remdesivir
Side effects
Theophylline
Viral diseases
COVID-19
Bradycardia
Remdesivir
Arrhythmias
cardiac
Online AccessGet full text

Cover

More Information
Summary:Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received theophylline and the other required a temporary pacemaker. Fortunately, the patients' heart rate and rhythm returned to normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir infusion may decrease the risk of adverse cardiovascular side effects.
ISSN:1735-5370
1735-8620
2008-2371
DOI:10.18502/jthc.v16i2.7390